March 22, 2023 03:43 PM EDTUpdated March 23, 08:45 AM
Pharma
FDA+

In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

Nicole DeFeudis

Editor

In­cyte tout­ed an ac­cel­er­at­ed ap­proval for its PD-1 reti­fan­limab in a rare skin can­cer on Wednes­day, rough­ly a year and a half af­ter the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times